Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Xuexin He"'
Publikováno v:
The Lancet Regional Health. Americas, Vol 32, Iss , Pp 100712- (2024)
Summary: Background: Understanding the survival outcomes associated with breast-conserving therapy (BCT) and mastectomy after preoperative systemic therapy (PST) enables clinicians to provide more personalized treatment recommendations. However, lack
Externí odkaz:
https://doaj.org/article/c6ff81558cca4cf8937cb01a0e2a20d9
Publikováno v:
Cancer Reports, Vol 6, Iss 8, Pp n/a-n/a (2023)
Abstract Background Because of the phenomenal success of treatment with monoclonal antibodies and antibody‐drug conjugates targeting human epidermal growth factor receptor 2 (HER2), most patients with early‐stage HER2‐positive breast cancer (HE
Externí odkaz:
https://doaj.org/article/5a03b990f5b24a6b803f3604a3ac0466
Autor:
Pan Sun, Peng Jiang, Qing Liu, Rong Zhang, Zongkui Wang, Haijun Cao, Xiangzhong Ye, Shangzhi Ji, Jinle Han, Kuilin Lu, Xuexin He, Jiajin Fan, Dawei Cao, Yu Zhang, Yongsheng Yin, Yunhua Chen, Xuemei Zhao, Shengliang Ye, Na Su, Xi Du, Li Ma, Changqing Li
Publikováno v:
PeerJ, Vol 11, p e15698 (2023)
Background Human parvovirus B19 (B19V) is a common contaminant found in plasma pools and plasma derivatives. Previous studies were mainly focused on limited aspects, further assessment of prevalence of B19V DNA and antibodies in plasma donors, the co
Externí odkaz:
https://doaj.org/article/ac52cc3398c7447880a3c75684be02ad
Autor:
Zun Wu, Yating Wu, Haofeng Gao, Xuexin He, Qiang Yao, Zhanglei Yang, Jinyi Zhou, Linting Ji, Jinwei Gao, Xuying Jia, Yong Dou, Xiaoyu Wang, Peng Shao
Publikováno v:
BMC Microbiology, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Vibrio vulnificus is a pathogenic bacterium that causes disease in marine fish, affecting fish farming and human health worldwide. In May 2021, in the Bohai Bay region, a disease broke out in commercially farmed pearl gentian grouper (♀Epi
Externí odkaz:
https://doaj.org/article/479482bb142a4155ba2dba90002ae00f
Publikováno v:
Cancer Medicine, Vol 11, Iss 7, Pp 1646-1658 (2022)
Abstract Background Recent retrospective studies have reported that breast‐conserving therapy (BCT) led to improved overall survival (OS) than mastectomy in some populations. We aimed to compare the efficacy of BCT and mastectomy using the SEER dat
Externí odkaz:
https://doaj.org/article/3efe024e971a46609f0e1a439e440e7a
Autor:
Binghao Li, Hao Qu, Jing Zhang, Weibo Pan, Meng Liu, Xiaobo Yan, Xin Huang, Xuexin He, Dong Lin, Sisi Liu, Ruting Guan, Yong Wu, Qiuxiang Ou, Hua Bao, Youbin Xu, Xue Wu, Yang Shao, Nong Lin
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-9 (2021)
Abstract Kinase fusions represent an important type of somatic alterations that promote oncogenesis and serve as diagnostic markers in lung cancer. We aimed to identify the landscape of clinically relevant kinase fusions in Chinese lung cancer and to
Externí odkaz:
https://doaj.org/article/f6cba414f712492aaf01108493a887d1
Autor:
Qing Zhao, Xuexin He, Xiyi Qin, Yu Liu, Han Jiang, Jing Wang, Shuang Wu, Rui Zhou, Congcong Yu, Suling Liu, Hong Zhang, Mei Tian
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer, which is relatively resistant to anti-programmed cell death-1 (α-PD1) therapy, characterized as non-immunogenic, dense stroma and accumulation of M2 tumor-as
Externí odkaz:
https://doaj.org/article/1578dde0fa2347b6ae398860288fa5a0
Publikováno v:
Cancer Reports.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bcdbaced91f993547149906956d9f7c
https://doi.org/10.1002/cnr2.1841
https://doi.org/10.1002/cnr2.1841
Autor:
Sai-Ching J. Yeung, Gabriel N. Hortobagyi, Francisco J. Esteva, Aiham Z. Qdaisat, Xiaolan Dai, Jiali Ji, Xuexin He
Supplementary Data from Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c9140e08abdcc6ef8d696a411dd245
https://doi.org/10.1158/1078-0432.22481421
https://doi.org/10.1158/1078-0432.22481421
Autor:
Sai-Ching Jim Yeung, Gabriel N. Hortobagyi, Francisco J. Esteva, Mei Tian, Jiali Ji, Xuexin He
Purpose:Adjuvant therapy for small, node-negative HER2-positive breast cancer (HER2+ BC) is controversial. We aimed to identify the subgroup that would benefit most from adjuvant chemotherapy and trastuzumab.Experimental Design:We reviewed records of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ae6d1407a7857b7cb7fd8e850b56e83
https://doi.org/10.1158/1078-0432.c.6528077.v1
https://doi.org/10.1158/1078-0432.c.6528077.v1